MetaVia share price logo

MetaVia

NASDAQ: MTVA

$1.53

+0.07

(+4.79%)

as on

MetaVia Stock Performance

as on August 25, 2026 at 2:15 pm IST

  • Day's Low

    $1.44
    $1.53
    downward going graph

    5.88%

    Downside

  • 52 Week's Low

    52 Week's High

    $0.97
    $19.03
    downward going graph

    36.86%

    Downside

    1143.72%

    Upside

    downward going graph

MetaVia share price movements today

Previous Close
$1.46
Open
$1.44
Volume
149.9K
Market Cap
$7.7M
Day's Low - High
$1.44 - $1.53
52 Week Low - High
$0.97 - $19.03

MetaVia Historical Returns

1 Month Return
-12.87 %
3 Month Return
+ 34.23 %
1 Year Return
-78.84 %
3 Year Return
0 %
5 Year Return
0 %

MetaVia Stock Fundamentals & Key Indicators

Check MetaVia market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.7M

EPS (TTM)

-4.07

Dividend Yield

0.00%

PE Ratio (TTM)

-0.36

Industry PE ratio

-1.5966015625

PEG Ratio

-0.0017591723712202811

Return On Equity TTM

-209.67%

MetaVia Stock Valuation

Track how MetaVia P/E has moved over time to understand its valuation trends.

MetaVia in the last 5 years

  • Overview

  • Trends

Lowest (-1.15x)

December 31, 2025

Industry (-1.60x)

December 31, 2025

Today (-1.15x)

December 31, 2025

Highest (-0.02x)

March 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -1.15x

MetaVia vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MetaVia with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$7.7MNA-0.360.00%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$25.3B-84.24%-7.98-12.57%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for MetaVia Stock including INR - Dollar returns

The MetaVia stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

MetaVia investment value today

Current value as on today

₹23,749

Returns

-₹76,251

(-76.25%)

Returns from MetaVia Stock

-₹78,267 (-78.27%)

Dollar Impact

₹2,016 (+2.02%)

Analyst Recommendation on MetaVia Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for MetaVia. Average target price of $14

Indian Investors' Interest in MetaVia Stock

Search interest for MetaVia Stock has decreased by -72% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-72% versus previous 30 day period

MetaVia Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
-
0
0
-
Operating Income
-6
-10
-6
-5
-3
-4
-3
-2
-4
-5
EBITDA
-6
-10
-5
-5
-3
-3
-3
-1
-3
-5
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-10
-5
-5
-3
-3
-3
-1
-3
-5
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-6
-10
-5
-5
-3
-3
-3
-1
-3
-5
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

MetaVia Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
0
0
0
0
0
0
Operating Income
-33
-15
-20
-29
-15
-19
-15
-28
-13
EBITDA
-33
-15
-20
-29
-15
-11
-12
-27
-12
Interest Expense
0
0
0
-
-
2
-
-
-
Depreciation
-
-
0
0
0
0
0
0
0
Income Before Tax
-33
-15
-21
-29
-15
-13
-12
-27
-12
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-33
-15
-21
-29
-15
-13
-12
-27
-12
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

MetaVia Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-6
-10
-5
-5
-3
-3
-3
-1
-3
-5
Operating Cash Flow
-6
-7
-5
-5
-4
-3
-2
-4
-4
-3
Investing Cash Flow
0
0
-
-
-
0
-
-
-
-
Financing Cash Flow
-
19
0
0
0
9
0
0
7
2
Change in Cash
-6
11
-6
-5
-4
6
-3
-3
3
-1

MetaVia Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-33
-15
-21
-29
-15
-13
-12
-27
-12
Operating Cash Flow
-26
-14
-7
-10
-15
-11
-10
-24
-15
Investing Cash Flow
-
0
-6
0
0
0
0
0
0
Financing Cash Flow
21
17
24
6
22
28
0
18
9
Change in Cash
-5
2
11
-3
6
16
-10
-6
-5

Mutual Funds that own MetaVia Stock

Check out the Mutual Funds with significant holdings in MetaVia.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.176849%
11651
VANGUARD INDEX FUNDS
0.033727%
2222

Global Institutional Holdings in MetaVia

Funds
Holdings
Vanguard
0.14%

Insights on MetaVia

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 538.4% return, outperforming this stock by 600.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.2% return, outperforming this stock by 571.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, MTVA stock has moved down by -60.3%

About MetaVia

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
OrganisationMetaVia
Headquarters545 Concord Avenue, Cambridge, MA, United States, 02138
IndustryBiotechnology
CEOMr. Hyung Heon Kim
E-voting on sharesClick here to vote

Key Management of MetaVia

Name

Title

Mr. Marshall H. Woodworth

Chief Financial Officer

Dr. Mi-Kyung Kim

Chief Scientific Officer

Mr. Robert Homolka

Senior Vice President of Clinical Operations

Dr. W. Christopher Fang M.D.

Consulting Chief Medical Officer & Advisor

Mr. Michael C. Pine

Senior Vice President of Business Development Advisor

Mr. Hyung Heon Kim

CEO, President & Director

FAQs

What is MetaVia share price today?

MetaVia share price today is $1.53 as on at the close of the market. MetaVia share today touched a day high of $1.53 and a low of $1.44.

What is the 52 week high and 52 week low for MetaVia share?

MetaVia share touched a 52 week high of $19.03 on and a 52 week low of $0.97 on . MetaVia stock price today i.e. is closed at $1.53,which is 91.96% down from its 52 week high and 58.37% up from its 52 week low.

What is MetaVia's market capitalisation today?

MetaVia market capitalisation is $0.00T as on .

How to invest in MetaVia Stock (MTVA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MetaVia on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MetaVia Shares that will get you 0.9804 shares as per MetaVia share price of $1.53 per share as on August 25, 2026 at 8:45 am IST.

What is the minimum amount required to buy MetaVia Stock (MTVA) from India?

Indian investors can start investing in MetaVia (MTVA) shares with as little as ₹95.735 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.35 in MetaVia stock (as per the Rupee-Dollar exchange rate as on ). Based on MetaVia share’s latest price of $1.53 as on August 25, 2026 at 8:45 am IST, you will get 6.5359 shares of MetaVia. Learn more about fractional shares .